Company intelligence / Profile preview

Pearl BioSystem

Strasbourg, Grand Est, Francepearlbiosystem.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Pearl BioSystem has developed a patented animal-free 3D organoid-based platform ("In Perlo" technology) to screen chemical libraries for anti-cancer activity. The company has demonstrated the identification of four anti-cancer molecules from an initial set of twelve tested in the cosmetics sector using its platform. No clinical results are available as the company operates at the preclinical/drug discovery stage.

Therapeutic areas: OncologyDermatology
Modalities: Small molecule (screening)Natural extract (screening)
Industry: Non-Drug Biotech

Partnerships

United BioChannels Inc. (USA) – marketing assessment partnerDolphin Partnership SASU – sales & marketing strategy advisor

Beyond the preview

Go deeper on Pearl BioSystem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl BioSystem.

Explore the full profile